186 related articles for article (PubMed ID: 10465111)
21. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
Mueller J; Gansauge S; Mattfeldt T
Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
[TBL] [Abstract][Full Text] [Related]
22. Detection of Ki-ras mutations by PCR and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis.
Lang SM; Heinzlmann M; Stratakis DF; Teschauer W; Loeschke K
Am J Gastroenterol; 1997 Dec; 92(12):2166-70. PubMed ID: 9399746
[TBL] [Abstract][Full Text] [Related]
23. [Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies].
Kurosawa M
Hokkaido Igaku Zasshi; 1994 May; 69(3):543-54. PubMed ID: 7927179
[TBL] [Abstract][Full Text] [Related]
24. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
25. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
26. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
27. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
[TBL] [Abstract][Full Text] [Related]
28. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
Hal DG; Stoica G
Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
[TBL] [Abstract][Full Text] [Related]
30. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636
[TBL] [Abstract][Full Text] [Related]
31. Genetics of melanoma predisposition.
Hayward NK
Oncogene; 2003 May; 22(20):3053-62. PubMed ID: 12789280
[TBL] [Abstract][Full Text] [Related]
32. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
33. P16 UV mutations in human skin epithelial tumors.
Soufir N; Molès JP; Vilmer C; Moch C; Verola O; Rivet J; Tesniere A; Dubertret L; Basset-Seguin N
Oncogene; 1999 Sep; 18(39):5477-81. PubMed ID: 10498902
[TBL] [Abstract][Full Text] [Related]
34. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
35. p53 and ras mutations in Ewing's sarcoma.
Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
[TBL] [Abstract][Full Text] [Related]
36. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
Soto JL; Cabrera CM; Serrano S; López-Nevot MA
BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
[TBL] [Abstract][Full Text] [Related]
37. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.
Papp T; Jafari M; Schiffmann D
J Cancer Res Clin Oncol; 1996; 122(9):541-8. PubMed ID: 8781568
[TBL] [Abstract][Full Text] [Related]
38. [Neurocutaneous melanosis and multiple congenital melanocytic naevi are associated with post-zygotic N-ras mutations].
Dereure O
Ann Dermatol Venereol; 2014 Apr; 141(4):314-5. PubMed ID: 24703650
[No Abstract] [Full Text] [Related]
39. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
40. BRAF mutations are common somatic events in melanocytic nevi.
Kumar R; Angelini S; Snellman E; Hemminki K
J Invest Dermatol; 2004 Feb; 122(2):342-8. PubMed ID: 15009715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]